06-255-I
Anti-JAK2 Antibody
from rabbit
Synonym(s):
Tyrosine-protein kinase JAK2, JAK2, Janus kinase 2
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.43
Recommended Products
biological source
rabbit
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human, rat, mouse
technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... JAK2(3717)
mouse ... Jak2(16452)
rat ... Jak2(24514)
General description
Tyrosine-protein kinase JAK2 (EC 2.7.10.2; UniProt Q62120; also known as JAK-2, Janus kinase 2) is encoded by the Jak2 (also known as Fd17) gene (Gene ID 16452) in murine species. JAK2 belongs to the family of non-receptor Janus tyrosine kinases that regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines cause the recruitment of Stat transcription factors to cytokine receptor. Subsequent phosphorylation by receptor-associated JAK2 causes Stat dimerization, nuclear translocation, and Stat-mediated target genes transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival, and host resistance to pathogens. Altering JAK/Stat signaling to reduce immune cells cytokine responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.
Immunogen
Epitope: Residues 758-776
KLH-conjugated linear peptide corresponding to residues 758-776 of mouse JAK2.
Application
Research Category
Signaling
Signaling
Research Sub Category
Developmental Signaling
Developmental Signaling
Quality
Evaluated by Western Blotting in RAW264.7 cell lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected JAK2 in 10 µg of RAW264.7 cell lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected JAK2 in 10 µg of RAW264.7 cell lysate.
Target description
~130 kDa observed. Uncharacterized band(s) may appear in some lysates.
Physical form
Format: Purified
Protein A purified
Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Other Notes
Concentration: Please refer to lot specific datasheet.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ning Ding et al.
Environmental and molecular mutagenesis, 60(4), 308-319 (2018-12-15)
At sites of chronic inflammation epithelial cells undergo aberrant DNA methylation that contributes to tumorigenesis. Inflammation is associated with an increase in reactive oxygen species (ROS) that cause oxidative DNA damage, which has also been linked to epigenetic alterations. We
Hiroki Akiyama et al.
Cancers, 12(2) (2020-02-14)
JAK2-V617F plays a key role in the pathogenesis of myeloproliferative neoplasm. However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells. We here demonstrate that the USP9X inhibitor WP1130 or EOAI3402143 (G9) inhibited
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service